Recombination Activating Gene 1 (RAG1) is a critical endonuclease that, together with RAG2, initiates V(D)J recombination—the process responsible for generating the vast diversity of T-cell receptors and immunoglobulins. Mutations in RAG1 lead to Severe Combined Immunodeficiency (SCID), Omenn syndrome, and severe autoimmunity, making it a primary target for gene correction therapies. Conversely, aberrant RAG1 activity is implicated in genomic instability and oncogenic translocations in lymphoid malignancies, positioning RAG1 as an emerging target for small-molecule inhibitors.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RAG1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RAG1 Recombinant Protein (Core Domain) High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. Optimized for in vitro cleavage assays. |
View RAG1 Products |
| Gene Delivery | RAG1 Promise-ORF / Lentivirus Full-length human RAG1 ORF for stable expression and cell-based reconstitution assays. |
View RAG1 Products |
| Benchmark Ab | Anti-RAG1 Recombinant Antibody Sequence-verified positive control for Western Blot, Immunofluorescence, and ChIP assays. |
View RAG1 Products |
| Validator | RAG1 siRNA Set Target-specific knockdown pool for validating target-dependent phenotypes. |
View RAG1 Products |
| Related Target A | RAG2 Essential cofactor; forms the active heterotetrameric endonuclease complex with RAG1 to bind Recombination Signal Sequences (RSS). |
View RAG2 Products |
| Related Target B | DCLRE1C (Artemis) Downstream endonuclease in the non-homologous end-joining (NHEJ) pathway, activated by DNA-PKcs to resolve RAG-induced hairpins. |
View DCLRE1C Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| RAG1 Protein Instability & Aggregation | Soluble Core-RAG1 recombinant construct designed with optimized solubility tags, sequence-verified to prevent aggregation in buffer systems. |
| Reconstitution of Active Complex | Matched RAG1 and RAG2 recombinant protein pairs available to ensure stoichiometric assembly in vitro. |
| Lack of Validated Controls | Highly specific recombinant benchmark antibodies and sequence-verified siRNA pools included for functional baseline establishment. |
| Off-Target Cleavage Assessment | High-purity reagents suited for genomic-wide off-target cleavage profiling and high-throughput screening. |
Live RAG1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for RAG1 is bifurcated into gene correction for immunodeficiencies and targeted inhibition for oncology. In genetic medicine, autologous hematopoietic stem cell (HSC) gene therapies utilizing lentiviral vectors or CRISPR/Cas9-mediated gene editing are progressing to correct RAG1-deficient SCID. In oncology, small-molecule inhibitors targeting the catalytic core of RAG1 are being investigated to prevent chemotherapy-induced relapses driven by aberrant V(D)J recombination in acute lymphoblastic leukemia (ALL).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (Lentiviral) | Academic Consortia, Orchard Therapeutics (historical interest) | RAG1-deficient SCID, Omenn Syndrome | Reconstitution validation (Need high-titer Lentiviral ORF and Western Blot-validated antibodies) |
| Gene Editing (CRISPR/Base Editors) | Preclinical Biotech, Academic Institutes | Severe Combined Immunodeficiency | Functional rescue assays (Need sequence-verified RAG1/RAG2 protein standards) |
| Small Molecule Inhibitors | Oncology-focused Biotechs | B-cell Acute Lymphoblastic Leukemia (B-ALL) | In vitro cleavage inhibition assays (Need active Core-RAG1/RAG2 complex proteins) |